Valuation: Avalo Therapeutics, Inc.

Market Cap 106.35Cr 91Cr 85Cr 78Cr 146.43Cr 10TCr 148.37Cr 1.01TCr 392.72Cr 5.11TCr 399.33Cr 390.64Cr 17TCr P/E 2026 *
-7.34x
P/E 2027 * -7.43x
Enterprise Value 64Cr 55Cr 51Cr 47Cr 88Cr 6.12TCr 89Cr 605.56Cr 236.15Cr 3.07TCr 240.12Cr 234.89Cr 10TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.06%
Yield 2027 * -
1 day+0.05%
1 week+1.23%
Current month+8.66%
1 month+5.37%
3 months+19.46%
6 months+39.55%
Current year+9.20%
1 week 19.32
Extreme 19.325
21.02
1 month 17.55
Extreme 17.55
21.02
Current year 12.51
Extreme 12.51
24.27
1 year 8.65
Extreme 8.65
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
18/08/26 Fiscal year

Chief Financial Officer

93,093 0.1760%
17/08/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
11/08/26 Sell

Executive/Senior Manager

-2,655 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%+1.23%+111.63%-24.89% 106.35Cr
-3.00%+2.27%+77.60%+109.33% 7.21TCr
+1.90%+23.53%+56.60%+97.76% 6.59TCr
+5.12%+25.22%+5.24%-0.82% 2.93TCr
+0.55%+1.64%-5.15%+471.68% 2.75TCr
+2.74%+12.98%+62.84%+28.14% 2.67TCr
+0.47%+6.12%+36.66%-13.79% 2.01TCr
+1.82%-6.67%+247.46%+393.10% 1.82TCr
+0.94%+3.36%+18.55%+532.94% 1.64TCr
+0.73%+5.54%+39.71%+153.07% 1.34TCr
Average +1.13%+7.67%+65.11%+174.65% 2.91TCr
Weighted average by Cap. +0.74%+9.45%+59.24%+157.14%

Financials

2026 *2027 *
Net sales - -
Net income -11Cr -9.23Cr -8.63Cr -7.9Cr -15Cr -1.03TCr -15Cr -101.98Cr -40Cr -517.64Cr -40Cr -40Cr -1.71TCr -13Cr -11Cr -10Cr -9.47Cr -18Cr -1.23TCr -18Cr -122.19Cr -48Cr -620.2Cr -48Cr -47Cr -2.05TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -58Cr -4.06TCr -59Cr -401.51Cr -156.57Cr -2.04TCr -159.21Cr -155.74Cr -6.74TCr -31Cr -26Cr -24Cr -22Cr -42Cr -2.92TCr -43Cr -289.34Cr -112.83Cr -1.47TCr -114.73Cr -112.23Cr -4.86TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
21/26/21 $19.83 +0.05% 5,69,829
20/26/20 $19.82 -4.48% 6,98,455
19/26/19 $20.75 +5.28% 9,99,045
18/26/18 $19.71 -1.20% 10,69,177
17/26/17 $19.95 +1.84% 6,46,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.83USD
Average target price
44.15USD
Spread / Average Target
+122.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock